Lumen Marketing Company

Lumen Marketing Company, established in 2012, is a Chennai-based Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates from its headquarters at 2, 2nd Floor, I Cross Street - 2nd Avenue, Ashok Nagar, Chennai 600083, India. As of the latest available data, Lumen Marketing Company employs between 10 to 19 individuals. The company is registered under the Corporate Identification Number (CIN) provided by the Ministry of Corporate Affairs, Government of India. In April 2023, Lumen Marketing Company filed a trademark application for its brand, indicating its commitment to brand protection and market presence. The company's revenue for the fiscal year 2022-2023 is not publicly disclosed. For more information, the company can be contacted through the details provided in the Kompass directory.

Lumen Marketing Company operates its manufacturing facilities in Chennai, India. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the plant's production capacity and certifications are not publicly available. The company emphasizes quality control and compliance with industry standards to ensure the safety and efficacy of its products.

The leadership team of Lumen Marketing Company includes Mr. S. Selvam, who serves as a Partner. Specific details regarding other key executives, such as the CEO, CFO, and their respective roles, are not publicly disclosed. The company's leadership is committed to maintaining high standards in pharmaceutical manufacturing and export operations.

Lumen Marketing Company exports its pharmaceutical products to various international markets, including Malaysia. In 2022, the company shipped 200 kilograms of POPCEE Vitamin C 500mg Chewable Tablets to Alpha Bio Medics Sdn Bhd in Malaysia. Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company is likely working to meet the regulatory requirements of these markets to expand its global footprint.

Lumen Marketing Company has made inroads into emerging markets, notably in Southeast Asia, with exports to Malaysia. The company's focus on Ayurvedic and herbal products aligns with the growing demand for traditional medicine in these regions. While specific details regarding WHO prequalification are not available, the company's commitment to quality suggests efforts to meet international standards, potentially facilitating access to other emerging markets in Africa and Latin America.

Lumen Marketing Company's export strategy appears to be concentrated in select international markets, with a notable presence in Malaysia. This focused approach may help the company manage resources effectively and build strong relationships in these regions. However, the lack of diversification into multiple markets could expose the company to risks associated with over-reliance on a limited number of markets. Strategic expansion into additional regions could mitigate this concentration risk and support sustainable growth.

Specific information regarding Lumen Marketing Company's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's focus on Ayurvedic and herbal products may present challenges in obtaining FDA approvals, as these products often require extensive documentation to demonstrate safety and efficacy. Engaging with regulatory consultants and investing in research and development could enhance the company's prospects in obtaining FDA approvals.

Details regarding Lumen Marketing Company's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. Achieving WHO prequalification and EU GMP certification would be significant milestones, enhancing the company's credibility and facilitating access to international markets. The company's commitment to quality suggests ongoing efforts to meet these standards.

Lumen Marketing Company holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has also obtained approvals from state drug controllers and export No Objection Certificates (NOCs), enabling it to export pharmaceutical products. These regulatory approvals underscore the company's compliance with Indian pharmaceutical manufacturing and export regulations.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Lumen Marketing Company by regulatory authorities. This absence of adverse regulatory actions indicates the company's adherence to industry standards and regulatory requirements.

Lumen Marketing Company operates in a competitive landscape with several key players in the Indian pharmaceutical export sector. Companies such as Lumen Pharmachem Private Limited, established in 2015, offer a range of pharmaceutical raw materials and formulations. While Lumen Pharmachem focuses on raw materials, Lumen Marketing Company's emphasis on finished pharmaceutical formulations differentiates its product offerings. The market is characterized by a mix of companies specializing in raw materials and those focusing on finished products, each catering to different segments of the pharmaceutical supply chain.

Lumen Marketing Company's focus on Ayurvedic and herbal products positions it uniquely in the market, catering to the growing global demand for traditional medicine. The company's commitment to quality and compliance with regulatory standards enhances its reputation among international clients. Additionally, the company's strategic location in Chennai, a hub for pharmaceutical manufacturing in India, provides logistical advantages for export operations.

Lumen Marketing Company is strategically positioned in the pharmaceutical export market, focusing on Ayurvedic and herbal formulations. The company's current strategic direction emphasizes quality manufacturing and compliance with international standards. Looking ahead, expanding its product portfolio to include generics, specialty drugs, biosimilars, and Contract Development and Manufacturing Organization (CDMO) services could open new revenue streams and enhance market competitiveness.

Lumen Marketing Company has demonstrated a consistent track record in exporting pharmaceutical products, with 29 shipments valued at $1.4 million USD between 2022 and 2026. The company's portfolio is concentrated, with its top two products—Ayurvedic and Extract formulations—accounting for 100% of its export value. This concentration indicates a focused product strategy but also suggests potential risks associated with market fluctuations affecting these specific products. The company's adherence to regulatory standards and commitment to quality further enhance its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's facility registration with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure the company holds Good Manufacturing Practice certification from the World Health Organization.

• EU GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practice standards.

• ISO Certifications: Check for relevant ISO certifications that demonstrate adherence to international quality management standards.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

Importers should undertake the following steps to ensure a thorough evaluation of Lumen Marketing Company:

• Verify Regulatory Approvals: Confirm the company's manufacturing licenses and export NOCs with the CDSCO and state drug controllers.

• Assess Product Quality: Request samples and review quality control documentation to ensure product standards meet international requirements.

• Evaluate Financial Stability: Review financial statements to assess the company's economic health and ability to fulfill large orders.

• Check References: Contact previous clients to gather feedback on the company's reliability and product quality.

• Inspect Manufacturing Facilities: If possible, conduct site visits to evaluate manufacturing processes and compliance with GMP standards.

Red flags to watch for include a lack of verifiable certifications, inconsistent product quality, and financial instability. Recommended pre-order checks involve obtaining comprehensive product documentation, including certificates of analysis, and ensuring clear communication regarding order terms and conditions.